Editas Medicine filed paperwork this morning for a $100 million initial public offering (IPO). The Cambridge, Massachusetts-based startup would become the first publicly-traded company specializing in gene editing, according to Bloomberg Business.
2021 Update
Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.